甲状腺乳头状癌中BRAF^V600E与TERT启动子联合突变的研究进展

Research progress of BRAF^V600E and TERT promoter mutations coexistence in papillary thyroid cancer

甲状腺乳头状癌(PTC)是甲状腺癌最常见的病理类型,其发病率在全球范围内迅速增长。V-raf鼠肉瘤滤过性病毒致癌同源体B1基因(BRAF)^V600E突变和端粒酶逆转录酶(TERT)启动子突变是PTC最常见的分子标志物,越来越多的研究发现两者联合突变在PTC的侵袭及预后中具有协同作用。该文对BRAF^V600E与TERT启动子联合突变在PTC中协同作用的最新研究进展进行综述。

Papillary thyroid cancer (PTC) is the most common pathological type of thyroid cancer, and its morbidity raises rapidly in the global world. V-raf murine sarcoma viral oncogene homolog B1 (BRAF)^V600E mutation and telomerase reverse transcriptase (TERT) promoter mutations are the most common molecular markers of PTC. Nowadays, more and more studies find that the coexistence of BRAFV600E and TERT promoter mutations plays a synergistic role in the invasion and prognosis of PTC. This article reviews the recent advance in the synergism of BRAF^V600E and TERT promoter mutations in PTC.